By: Mike Bassett From: medpagetoday.com The agents have significantly extended progression-free survival, but what are the options post-progression? The development and approval of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been called game-changers in the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Treatment with these drugs — palbociclib, ribociclib, …
Acquired ESR1 Mutations Predict Poor Benefit from Further AI Therapy in Metastatic Breast Cancer
By: Christina Bennett, MS From: cancertherapyadvisor.com Patients with hormone receptor (HR) positive metastatic breast cancer who acquired ESR1 mutations during prior aromatase inhibitor therapy had worse survival when treated with the aromatase inhibitor exemestane compared with fulvestrant, a combined analysis of the phase 3 SoFEA and EFECT trials found. The results were recently reported in Clinical Cancer Research. The EFECT …
Novel Combination Shows Survival Benefit in HER2-Positive Metastatic Breast Cancer
By: Jessica Skarzynski From: curetoday.com The combination of pyrotinib plus Xeloda (capecitabine) provides a better progression-free survival (PFS) rate than Tykerb (lapatinib) plus Xeloda in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with Herceptin (trastuzumab) and chemotherapy, according to recent data. Although patients with HER2-positive metastatic breast cancer have several therapy options to choose from, not …
Alpha-TEA and Concurrent Trastuzumab Under Exploration in Refractory HER2+ Breast Cancer
By: Brittany Cote From: onclive.com William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research. Concurrent treatment with α-tocopheryloxyacetic acid (TEA) and trastuzumab (Herceptin) could possess the potential to induce clinical activity and augment type 1 (Th1) antitumor immunity in patients with HER2-positive metastatic breast cancer who have …
Surgery for Metastatic Breast Cancer Does Not Improve Overall Survival
By: Benjamin Ryan From: cancerhealth.com A new randomized study sought to clarify results from previous studies that suggested there would be a benefit from such local treatment. Women diagnosed with breast cancer that is already at Stage IV, meaning metastatic cancer that has spread to other parts of the body, do not experience a benefit in overall survival from surgery …
Alteogen confirms safety, efficacy of HER2 breast cancer therapy
By: Shim Hyun-tai From: koreabiomed.com The American Society of Clinical Oncology (ASCO) is one of the most noteworthy events in the global biotech industry as it provides an opportunity to gauge the clinical success of pipelines for pharmaceuticals on the global stage. This is the sixth in a series of articles Korea Biomedical Review publishes to present the key clinical …
Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
By: Denise Myshko From: onclive.com Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program. The median PFS was 12.5 months (95% …
Scientists identify obscure protein responsible for advanced breast cancer
By: University of South Australia From: medicalxpress.com South Australian scientists have made a critical breakthrough, discovering how an obscure protein causes breast cancer to develop and grow more quickly. High levels of a protein called Creld2 have been linked to the most aggressive types of breast cancer with lower survival rates, according to Associate Professor Michael Samuel, a senior UniSA …
Novel biomarkers predict benefit with immunotherapy in metastatic breast cancer
By: European Society for Medical Oncology From: medicalxpress.com Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020. The biomarkers are an increase in the number …
Improving Upon Treatment Standards in HR+ Breast Cancer
By: Nichole Tucker From: targetedonc.com In an interview with Targeted Oncology, Erica Mayer, MD, discussed advances in the treatment landscape of HR-positive, HER2-negative breast, primarily with endocrine therapy and CDK4/6 inhibition. Treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is traditionally executed with the use of endocrine therapy. With the emergence of targeted therapies for the treatment of this disease, …